Synthetic lipid nanoparticles targeting steroid organs

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1996-2003

  Mérian, Juliette ^a,b   Boisgard, Raphaël ^a   Decleves, Xavier ^c   Thezé, Benoît ^a   Texier, Isabelle ^b   Tavitian, Bertrand ^a,d  

^a DIF   (France)

^b CEA LETI   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

Biodistribution; In vivo imaging; Lipid nanoparticles; Lipoproteins; Pharmacokinetics

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOTRICARBOCYANINE; CARBON CHOLESTERYL OLEATE C 14; CHEMICAL COMPOUND; CHOLESTEROL; DRUG CARRIER; FLUORESCENT DYE; LIPIDOT; PHOSPHOLIPID; POLY(ETHYLENEGLYCOL); RADIOPHARMACEUTICAL AGENT; TRITIUM CHOLESTERYLHEXADECYL ETHER; UNCLASSIFIED DRUG; LIPID; LIPOPROTEIN; NANOPARTICLE; STEARIC ACID; STEARIC ACID DERIVATIVE; STEROID;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CONTROLLED STUDY; FLUORESCENCE IMAGING; IN VIVO STUDY; ISOTOPE LABELING; MATERIAL COATING; MOUSE; NANOTECHNOLOGY; NONHUMAN; OVARY; PARTICLE SIZE; PRIORITY JOURNAL; RADIOACTIVITY; TISSUE DISTRIBUTION; ANIMAL; BIODISTRIBUTION; CHEMISTRY; FEMALE; IN VIVO IMAGING; LIPID NANOPARTICLES; METABOLISM; PHARMACOKINETICS; SYNTHESIS; MEDICINAL CHEMISTRY;

BIODISTRIBUTION; IN VIVO IMAGING; LIPID NANOPARTICLES; LIPOPROTEINS; PHARMACOKINETICS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUG CARRIERS; FEMALE; LIPIDS; MICE; NANOPARTICLES; STEARIC ACIDS; STEROIDS;

EID: 84891703726     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121657     Document Type: Article

References (40)

1. Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454-477.
2. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161-172.
3. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196.
4. Delmas T, Couffin AC, Bayle PA, et al. Preparation and characterisation of highly stable lipid nanoparticles with amorphous core of tuneable viscosity. J Colloid Interface Sci. 2011;360:471-481.
5. Delmas T, Piraux H, Couffin AC, et al. How to prepare and stabilize very small nanoemulsions. Langmuir. 2011;27:1683-1692.
6. Gravier J, Navarro F, Delmas T, et al. Lipidots: a biocompatible alternative to quantum dots for in vivo fluorescence imaging. J Biomed Opt. 2011;16: 096013.
7. Goutayer M, Dufort S, Josserand V, et al. Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm. 2010;75:137-147.
8. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
9. Li M, Al-Jamal KT, Kostarelos K, et al. Physiologically based pharmacokinetic modeling of nanoparticles. ACS Nano. 2010;4:6303-6317.
10. Chen B, Jerger K, Fréchet JM, et al. The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly(acrylic acid) comb polymers. J Control Release. 2009;140:203-209.
11. Sadekar S, Ray A, Janat-Amsbury M, et al. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules. 2011;12:88-96.
12. Cao W, Ng KK, Corbin I, et al. Synthesis and evaluation of a stable bacteriochlorophyll-analog and its incorporation into high-density lipoprotein nanoparticles for tumor imaging. Bioconjug Chem. 2009;20:2023-2031.
13. Derksen JTP, Morselt HWM, Scherphof GL. Processing of different liposome markers after in vitro uptake of immunoglobulin-coated liposomes by rat liver macrophages. Biochim Biophys Acta. 1987;931:33-40.
14. Kawakami S, Munakata C, Fumoto S, et al. Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs. J Pharm Sci. 2001;90: 105-113.
15. Pool GL, French ME, Edwards RA, et al. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids. 1982;17:448-452.
16. Hoarau D, Delmas P, David S, et al. Novel long-circulating lipid nanocapsules. Pharm Res. 2004;21:1783-1789.
17. Khalid MN, Simard P, Hoarau D, et al. Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors. Pharm Res. 2006;23:752-758.
18. Rivkin I, Cohen K, Koffler J, et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors. Biomaterials. 2010;31:7106-7114.
19. Mougin-Degraef M, Bourdeau C, Jestin E, et al. Doubly radiolabeled liposomes for pretargeted radioimmunotherapy. Int J Pharm. 2007;344:110-117.
20. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163:2113-2126.
21. Moghimi SM, Hunter AC, Andersen TL. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu Rev Pharmacol Toxicol. 2012;52:481-503.
22. Almeida JPM, Chen AL, Foster AB, et al. In vivo biodistribution of nanoparticles. Nanomedicine. 2011;6:815-835.
23. Sasatsu M, Onishi H, Machida Y. In vitro and in vivo characterization of nanoparticles made of MeO-PEG amine/PLA block copolymer and PLA. Int J Pharm. 2006;317:167-174.
24. Choi HS, Liu W, Misra W, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165-1170.
25. Longmire MR, Ogawa M, Choyke PL, et al. Biologically optimized nanosized molecules and particles: more than just size. Bioconjug Chem. 2011;22:993-1000.
26. Bruns OT, Ittrich H, Peldschus K, et al. Real-time magnetic resonance imaging and quantification of lipoprotein metabolism in vivo using nanocrystals. Nat Nanotechnol. 2009;4:193-201.
27. Keegan CE, Hammer G. Recent insights into organogenesis of the adrenal cortex. Trends Endocrinol Metab. 2002;13:200-208.
28. Hershkovitz L, Beuschlein F, Klammer S, et al. Adrenal 20alpha-hydroxysteroid dehydrogenase in the mouse catabolizes progesterone and 11-deoxycorticosterone and is restricted to the X-zone. Endocrinology. 2007;148:976-988.
29. Zheng G, Chen J, Li H, et al. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci USA. 2005;102: 17757-17762.
30. Ng KK, Lovell JF, Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res. 2011;44:1105-1113.
31. Bricarello DA, Smolowitz JT, Zivkovic AM, et al. Reconstituted lipoprotein: a versatile class of biologically-inspired nanostructures. ACS Nano. 2011; 5:42-57.
32. Göppert TM, Müller RH. Protein adsorption patterns on poloxamer-and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur J Pharm Biopharm. 2005;60:361-372.
33. Göppert TM, Müller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm. 2005;302:172-186.
34. Lecompte M-F, Bras A-C, Dousset N, et al. Binding steps of apolipoprotein A-I with phospholipid monolayers: adsorption and penetration. Biochemistry. 1998;37:16165-16171.
35. Lund-Katz S, Nguyen D, Dhanasekaran P, et al. Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles. J Lipid Res. 2010;51:606-617.
36. Cullis PR, Chonn A, Semple SC. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Deliv Rev. 1998;32:3-17.
37. Zhang L, Yan F, Zhang S, et al. Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein. Nat Chem Biol. 2012;8:342-349.
38. Connelly MA, Williams DL. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol Metab. 2003;14:467-472.
39. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol. 2010;28:4038-4044.
40. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer. 2011;2:85-90.